|
Status
|
In progress
|
| Process |
STA
|
| ID number |
1019
|
Provisional Schedule
| Expected publication |
25 April 2018 |
Project Team
Email enquiries
Consultees
| Companies sponsors |
Merck Sharp & Dohme (pembrolizumab) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
Commentators
| Comparator companies |
Accord Healthcare (CAU not returned, not participating) |
| |
Actavis UK (CAU not returned, not participating) |
| |
Dr Reddy's Laboratories (CAU not returned, not participating) |
| |
Eli Lilly (CAU not returned, not participating) |
| |
Hospira (CAU not returned, not participating) |
| |
Medac (CAU not returned, not participating) |
| |
Peckforton Pharmaceuticals (CAU not returned, not participating) |
| |
Sanofi (CAU not returned, not participating) |
| |
Seacross Pharmaceuticals (CAU not returned, not participating) |
| |
Sun Pharmaceuticals UK (CAU not returned, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
| |
National Cancer Research Institute |
|
Date
|
Update
|
|
16 March 2018 - 03 April 2018
|
Final appraisal determination |
|
23 January 2018
|
The company, Merck Sharp & Dohme, submitted a new value proposition to consider the use of pembrolizumab within the cancer drugs fund (CDF) for this population. This has been considered, and we will be producing a FAD which will be placed on the NICE website in due course. |
|
26 October 2017
|
Committee meeting: 2 |
|
03 August 2017 - 24 August 2017
|
Appraisal consultation |
|
17 August 2017
|
The company has requested to submit additional evidence to this appraisal which NICE have agreed to accept. As a consequence, to allow time for this to be reviewed, this will no longer be discussed at the technology appraisal committee meeting on 30 August 2017. The discussion has now been rescheduled to 26 October 2017. |
|
31 May 2017
|
Committee meeting: 1 |
|
08 December 2016
|
Invitation to participate |
|
22 July 2016
|
Referral |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance